Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Contraception. 2023 Jul 13;126:110118. doi: 10.1016/j.contraception.2023.110118

Table 1:

Characteristics of patients undergoing second-trimester dilation and evacuation (D&E) for intrauterine fetal demise (n=64) and patients undergoing second-trimester D&E for induced abortion (n=128) at the University of California, Davis Medical Center from January 1, 2019 to May 31, 2021.

Characteristic Patients undergoing D&E for IUFD Patients undergoing D&E for induced abortion p value
Total patients 64 128
Patient age (years) 31.6 ± 5.2 30.8 ± 5.4 0.349 T
Gravidity 4 (2, 6) 3 (2, 5) 0.304 W
   1 11 (17.2) 17 (13.3)
   2 7 (10.9) 30 (23.4)
   3+ 46 (71.9) 81 (63.3)
Parity 2 (1, 3) 1 (1, 2) 0.124 W
   0 14 (21.9) 28 (21.9)
   1 12 (18.8) 42 (32.8)
   2 17 (26.6) 30 (23.4)
   3+ 21 (32.8) 28 (21.9)
Race **
   White 39 (60.9) 65 (50.4)
   Black/African American 5 (7.8) 28 (21.7)
   Asian 8 (12.5) 12 (9.3)
   American Indian/Alaska Native 1 (1.6) 3 (2.3)
   Native Hawaiian/Pacific Islander 1 (1.6) 1 (0.8)
   More than one race 2 (3.1) 4 (3.1)
   Unknown/Not Reported/Other 6 (9.4) 10 (7.8)
Ethnicity **
   Hispanic or Latina 16 (25.0) 35 (27.3)
   Unknown/Not Reported 1 (1.6) 4 (3.1)
BMI 30.2 ± 7.6 29.4 ± 7.1 0.467 T
   Underweight [<18.5) 1 (1.6) 1 (0.8)
   Normal [18.5-25) 15 (23.4) 35 (27.3)
   Overweight [25-30) 19 (29.7) 41 (32.0)
   Class 1 obesity [30-35) 13 (20.3) 26 (20.3)
   Class 2 obesity [35-40) 12 (18.8) 15 (11.7)
   Class 3 obesity [>40] 4 (6.3) 10 (7.8)
History of diabetes 6 (9.4) 3 (2.3) 0.062 F
History of hypertension 8 (12.5) 8 (6.3) 0.140 C
History of bleeding or clotting problems* 7 (10.9) 7 (5.5) 0.237 F
Previous Cesarean section 15 (23.4) 30 (23.4) >0.999 C
Previous IUFD 3 (4.7) 0 (0) 0.036 F
GA by best dating (weeks) 17.7 (16.2, 20.5) 18.1 (16.0, 20.4) >0.999 W
GA size-date discrepancy (weeks) 1.8 (0, 3.8) 0 (0, 0.6) <0.001 W
Fetal anomaly, suspected or diagnosed 26 (40.6) 33 (25.8) 0.036 C
Preoperative bleeding risk <0.0001 C
   Low 3 (4.7) 56 (43.8)
   Moderate 56 (87.5) 69 (53.9)
   High 5 (7.8) 3 (2.3)
Preoperative hemoglobin (g/dL) 12.5 ± 1.3 12.0 ± 1.1 0.017 F
Preoperative platelet count (x109/L) 233.2 ± 64.5 248.6 ± 65.5 0.127 F

Data are reported as n (%), mean ± standard deviation, or median (first quartile, third quartile) with p values calculated using chi-square or Fisher’s exact test for categorical variables, t test for normal numeric variables, and Wilcoxon rank sum test for non-normal numeric variables. IUFD, intrauterine fetal demise; BMI, body mass index; GA, gestational age.

*

Includes uterine fibroids; inflammatory bowel disease with blood in stool at time of presentation; venous thrombosis; pulmonary embolism; stroke; sickle cell trait; chronic idiopathic thrombocytopenia; and anemia, abnormal uterine bleeding, and obstetric hemorrhage requiring transfusion or hospitalization.

**

For descriptive use only; no tests of association performed for race or ethnicity.

C

Chi square test

F

Fisher’s exact test

T

t test

W

Wilcoxon rank sum test